We currently don't have sufficient analyst coverage to forecast growth and revenue for OPC Pharmaceutical.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth
16.2%
Revenue growth rate
n/a
Future return on equity
n/a
Analyst coverage
None
Last updated
n/a
Recent future growth updates
No updates
Recent updates
In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as OPC Pharmaceutical has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
HOSE:OPC - Analysts future estimates and past financials data (VND Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
3/31/2026
1,128,779
95,364
-39,475
-12,217
N/A
12/31/2025
1,122,987
98,499
41,675
59,928
N/A
9/30/2025
1,057,743
96,867
62,581
81,036
N/A
6/30/2025
979,012
87,083
46,172
58,219
N/A
3/31/2025
957,891
89,350
33,875
39,132
N/A
12/31/2024
968,576
94,408
12,147
23,725
N/A
9/30/2024
951,225
87,325
99,190
109,573
N/A
6/30/2024
979,668
96,456
65,248
80,436
N/A
3/31/2024
1,027,903
109,574
256,025
272,313
N/A
12/31/2023
1,004,887
103,557
243,317
255,359
N/A
9/30/2023
983,349
115,809
34,975
48,848
N/A
6/30/2023
1,039,274
121,611
134,291
145,354
N/A
3/31/2023
989,310
114,485
-51,725
-44,163
N/A
12/31/2022
1,171,614
128,118
28,688
36,088
N/A
9/30/2022
1,225,353
129,058
299,705
304,849
N/A
6/30/2022
1,245,135
126,068
269,350
269,953
N/A
3/31/2022
1,225,233
115,178
259,878
266,104
N/A
12/31/2021
1,123,728
112,961
181,809
190,721
N/A
9/30/2021
1,062,751
105,759
78,696
100,813
N/A
6/30/2021
978,151
94,020
35,118
68,113
N/A
3/31/2021
977,763
98,960
57,080
88,378
N/A
12/31/2020
965,591
94,798
93,340
124,161
N/A
9/30/2020
906,638
85,631
64,759
87,669
N/A
6/30/2020
961,404
92,235
98,510
116,101
N/A
3/31/2020
1,011,614
95,729
112,952
133,825
N/A
12/31/2019
989,390
90,392
N/A
56,057
N/A
9/30/2019
1,021,060
95,010
N/A
48,588
N/A
6/30/2019
977,318
88,435
N/A
12,161
N/A
3/31/2019
963,910
87,648
N/A
-36,160
N/A
12/31/2018
1,002,478
88,013
N/A
1,542
N/A
9/30/2018
964,915
82,013
N/A
31,900
N/A
6/30/2018
968,353
84,157
N/A
30,397
N/A
3/31/2018
946,446
80,677
N/A
22,652
N/A
12/31/2017
944,850
78,262
N/A
103,621
N/A
9/30/2017
928,090
80,059
N/A
90,007
N/A
6/30/2017
901,043
75,868
N/A
90,506
N/A
3/31/2017
870,910
72,526
N/A
145,985
N/A
12/31/2016
790,405
70,251
N/A
106,517
N/A
9/30/2016
718,866
65,252
N/A
60,556
N/A
6/30/2016
684,761
61,213
N/A
65,918
N/A
3/31/2016
672,670
62,380
N/A
59,193
N/A
12/31/2015
663,213
63,238
N/A
84,022
N/A
9/30/2015
658,244
68,056
N/A
135,057
N/A
6/30/2015
634,702
62,077
N/A
102,528
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if OPC's forecast earnings growth is above the savings rate (3.2%).
Earnings vs Market: Insufficient data to determine if OPC's earnings are forecast to grow faster than the VN market
High Growth Earnings: Insufficient data to determine if OPC's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if OPC's revenue is forecast to grow faster than the VN market.
High Growth Revenue: Insufficient data to determine if OPC's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OPC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/27 12:08
End of Day Share Price
2026/06/26 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OPC Pharmaceutical Joint Stock Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.